Monday, October 29, 2012

Tackling Nerve Pain


Motivation: Pain is the bane of internists - particularly neuropathic pain. The gnawing, burning pain keeps people (patients and internists) up all night debating whether to use IV opioids.  And, gabapentin hardly seems up to the job.  There were several instances last year when even mega-doses of gabapentin failed to lessen the pain.  I often wondered at that point, what next?  To start a new agent, should I stop gabapentin? (And, is this pain real?)

During a clinic this year, one of the attendings pointed out a helpful trial that attempted to deal with failed control of neuropathic pain.  The trial tested combination of tricylcic agent nortriptyline with gabapentin.  As way of background, gabapentin is an alkylated analogue of GABA that is actually thought to work through modulating calcium channel subunits.  Nortriptyline is derived from amitriptyline with multiple effects including blockade of norepinephrine and serotonin re-uptake, blockade of sodium channels, anti-cholinergic actions, and antagonism of NMDA receptors.

Paper: Gilron, I., Bailey, J.M., Tu, D. et. al. "Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial" Lancet (2009); 374: 1252.

Methods: Double-blind crossover trial in patients with diabetic polyneuropathy and postherpetic neuralgia with persistent neuropathic pain. Randomized trial of three treatments - gabapentin, nortriptyline, and combined gabapentin and nortriptyline.  In crossover design, each of three groups spent 6 weeks in each of the three treatment groups (received placebo pill for second agent when getting just gabapentin or nortriptyline).  After 6 weeks, each of the groups were switched to one of the other three treatment assignements.  During the trial period, drug doses were titrated to maximum tolerated dose.  Primary outcome was mean daily pain (0-10 rating scale).

Results:
Subjects: The trial enrolled total of 56 participants.  Of these patients, 40 had diabetic polyneuropathy and 16 had post-herpetic neuralgia.  All of the patients were white with men comprising 65% of diabetic groups and 56% of post-herpetic neuralgia group.  In the diabetic group, 20% were taking opioids with about 33% having been exposed to prior tricyclic and 20% having been exposed to gabapentin/pregabalin.  Similarly, in the post-herpetic neuralgia group, 25% were taking opioids with about 31% having been exposed to prior tricyclic and 44% having been exposed to gabapentin/pregabalin.

Gabapentin vs. Nortriptyline: As monotherapy, both gabapentin and nortriptyline achieved lower daily pain intensity compared to baseline (5.4 in baseline vs. 3.2 for gabapentin; 5.4 vs. 2.9 for nortriptyline). The pain rating is significantly lower from baseline but is not significantly different between drugs.  Similarly, neither drug was superior to each other in terms of worst pain in 24 hours, least pain in 24 hours, or percentage pain relief on treatment.

Combination Therapy: Combined nortriptyline and gabapentin was significantly superior to gabapentin and nortriptyline monotherapy in terms of daily pain intensity (2.3 in combination vs 3.2 for gabapentin alone, p=0.001; 2.3 vs 2.9 for nortriptyline, p=0.02).  Combination therapy also provided better percentage pain relief on treatment (63.4% vs. 48.1% for gabapentin, p=0.007; vs. 45.7% for nortriptyline, p=0.002).  In secondary analysis, Beck depression score was significantly better for combination therapy compared to nortriptyline (5.4 vs. 6.8 for nortriptyline, p=0.01).  Self-reprorted vitality was also higher with gabapentin and combination therapy compared to nortriptyline alone. Depression scores were not different between combination therapy and gabapentin.

Dosage: As monotherapy, average maximum doses of gabapentin was 2433 mg/day while that of nortriptyline was 61.6 mg/day.  In combination, average gabapentin dose was 2180 mg/day and nortriptyline dose was 50.1 mg/day.

Adverse Effects: No serious side effects were noted.  Dry mouth was more frequent with nortriptyline while inability to concentrate was more frequent with gabapentin.

Discussion: For patients with poorly controlled neuropathic pain, combination therapy with nortriptyline and gabapentin was superior to monotherapy.  While both drugs appeared to be equivalent in terms of controlling pain, I was surprised at the worse depression scores and decreased vitality with nortriptyline monotherapy compared to gabapentin.  Given the alternate use as anti-depressant, I would have expected nortriptyline to be at least as good as gabapentin in terms of mood.  This analysis is, of course, secondary and limited by the small number of subjects (56 total patients), but given the limited data, I would start with gabapentin monotherapy and then add nortriptyline as an adjunctive agent.  Another cautionary note is that the tolerated doses of gabapentin in the trial was more than 2000 mg/day.  With the usual starting dose of 300 mg thrice daily, the drug needs to be significantly uptitrated prior to pronouncing therapeutic failure.

Sunday, October 21, 2012

Preserve your wisdom

Motivation: I dislike going to the dentist.  I do not mind the whining drill, but after finishing poking through my teeth, every dentist tells me to take out all my wisdom teeth.  And, I have resisted for more than a decade.  In few other fields of medicine are prophylactic painful procedures so prevalent for a less than life-threatening outcome - a cavity in a wisdom tooth.  To further solidify my argument for my next visit, I wondered about the data backing this recommendation.

As way of background on dentistry, current American guidelines recommend extracting wisdom teeth that fail to erupt completely ("impacted wisdom teeth" in dentistry parlance) preferably during adolescence.  Since no randomized trials exist in adults, reviewed below is a paper which examines the strength of existing evidence.

Paper:  Shallu, B. and Rajesh, S. "Is it Wisdom to Remove a Wisdom Tooth? - Extraction versus nonextraction Management of Impacted Tooth" Ind. J. of Den. Sci. (2010); 2: 4-6

Results:
Incidence of Pathology in Wisdom Teeth: When followed for four years, about 10% of non-erupted wisdom teeth result in adults develop surrounding gingival inflammation or pericoronitis.  There is low incidence (less than 1%) of root resorption in surrounding molar teeth as a result of non-erupted wisdom teeth.  Incidence of inflammation spreading from wisdom teeth to surrounding teeth (ie. causing dental caries) is estimated at 1 to 4.5%.

Early Removal of Wisdom Teeth vs. Later Removal: In post-intervention series, persons aged 35 to 83 years of age were less likely to experience dry socket, secondary infection, and parasthesias compared to those aged 12-24.  The highest risk of complications occurred in people aged 25 to 34 years.

Erupting Wisdom Teeth Causing Crowding of Anterior Teeth: Primarily theoretical prediction without substantial longitudinal clinical data.  (From a Cochrane review), a single trial comparing outcomes at 5 years did not find substantial differences between tooth extraction and observation.

Discussion: I think that I will take the one out of ten chance that keeping wisdom teeth may result in pathology in the next four years.  There are no data to support benefits of early asymptomatic extraction.  In fact, in England, the governmental health organization, NICE, recommended against prophylactic removal of asymptomatic wisdom teeth.  A similar Cochrane review on this topic also found insufficient evidence.  I was personally surprised at the lack of data given the estimated mutli-billion dollar industry among oral surgeons dedicated to wisdom tooth removal.  I think that like other similar problems in medicine such as with gallstones, preventive intervention may not be justified on a population basis. 

Friday, October 12, 2012

Is High Fructose Corn Syrup Unhealthy?


Motivation: Somehow we all know it - high fructose corn syrup makes you gain weight. I cannot remember when I first heard it or when I last read something about it, but this notion is spreading from the health community outwards.  I even had a patient ask me about avoiding foods with high fructose corn syrup.  Not knowing much beyond rumors, I felt that it was time to investigate the merits of different kinds of sugars.  What is the data linking high fructose corn syrup to the epidemic of obesity and diabetes?

As way of background, regular sugar consists of sucrose, which is a disaccharide of fructose and glucose.  High fructose corn syrup (HFCS), in contrast, consists of monosaccharides with varying concentrations of fructose and glucose (from 42% to 90% fructose).

Paper: Forshee, R.A., Storey, M.L., Allison, D.B. et. al. "A Critical Examination of the Evidence Relating High Fructose Corn Syrup and Weight Gain" Crit. Rev. in Food Sci. and Nut. (2007); 47:561-582.

Method: Systematic review conducted by expert panel convened by Center for Food, Nutrition, and Agriculture Policy to examine the evidence linking HFCS and changes in BMI/body weight.

Results:
The strength of evidence from different classes of evidence are summarized below. Given the breadth of evidence, only significant studies are presented:

Ecological Studies: These are large scale studies linking trends between food consumption and health measures.  Between 1909 to 1997, incidence of type 2 diabetes was positively and significantly correlated with corn syrup intake along with intake of fat, total carbohydrate, protein, and total energy.  Using food-consumption data to estimate sweetener consumption from 1962 to 2000, the authors found a 74 kcal/person increase in per capita sweeter availability in this time period.  No causality with disease is implicated in this study.

Cross-Sectional Studies: Four studies were identified examining relationship between soft or sweetened drink consumption (proxy for HFCS) and obesity.  Three out of four studies found that sweetened regular soft drinks were not significantly associated with BMI. One study among European American children showed positive association between overweight and sweetened beverages along with association with consumption of increased total food and beverages.

Longitudinal Studies: Four studies examined growing children and sweetened drink consumption.  Three out of these four studies did not find any association in excess of total calories consumed.  One study showed that over 19 months, BMI increased by 0.24 units for every additional serving of sweetened drink.

Among adults, when 38,480 women health professionals were followed, total caloric sweetener (fructose or glucose) consumption did not correlate to risk of type 2 diabetes.  Another study also examined sweetened beverage consumption among women 24-44 for 15 years and did not find excess weight gain among high consumers of sweetened beverages.  The study did find that women who moved from low consumption to high consumption were at higher risk of weight gain.

Controlled Trial: Only one RCT has been performed to test this question among children 7-11 years of age.  The intervention group received education emphasizing healthy diet and discouraged sweetened and carbonated beverages.  Mean percentage of overweight and obese children decreased in the intervention arm.

Discussion: In summary, the evidence linking high fructose corn syrup and obesity is circumstantial at best.  The overall upward trend in obesity and diabetes can also be explained by increased caloric intake - which has paralleled the weight gain the past few decades.  Of course, the evidence also does not conclusively refute the hypothesis that HFCS is in part responsible for accelerating obesity.  Given the complex interactions between food habits and general health habits, it is hard to see how anything besides a randomized trial can provide more definitive evidence.  For now, though, to avoid obesity and diabetes, limiting caloric intake is likely a better idea than avoiding high fructose corn syrup.

Saturday, September 8, 2012

Filtering out Clots

Motivation: Anti-coagulation for acute DVT and PE does not make complete sense to me.  I understand that anti-coagulation stops clot extension, but what about the big DVT stranded in the vein?  Nothing really prevents it from chipping off in the next few days to the pulmonary vasculature.  Seems to me that a temporary IVC filter while beginning anti-coagulation may prevent PE while buying time for the DVT to be naturally absorbed.  Two days ago, while contemplating this apparently novel strategy, I was surprised to see that this idea had not only been thought about but also been tested through a randomized trial.


Methods: Multicenter, open label randomized trial in France.  Two-by-two factorial design randomizing patients with proximal DVT to permanent IVC filter vs no filter and to low molecular weight heparin (LMWH) vs unfractionated heparin.  Patients on LMWH and UFH were transitioned to coumadin treatment starting on day 4.  Inclusion criteria were adults with proximal DVT with or without concomitant PE.  Important exclusion criteria were contraindication to anti-coagulation and hereditary thrombophilia.  Primary outcome was occurrence of pulmonary embolism within first 12 days after randomization.  All patients were evaluated first by V/Q scan and then by pulmonary angiography if necessary.  Patients were followed for two years.

Results:
Cohort: In total, 400 patients were recruited and randomized to IVC filter (200 to filter, 200 to no filter) and anti-coagulation (195 to LMWH and 205 to UFH).  Mean age was 72 years and 47.5% were male.  49% of patients presented with PE in addition to DVT.  About 35% had prior thromboembolism and 14% had known cancer.  About 11% had surgery in the past 60 days.

Primary Outcome: Within the first 12 days, there were 2 PE in group with filter compared to 9 in the group with no filter (OR: 0.22, CI: 0.05-0.90), p=0.03.  There were 5 deaths in each group.  Within the first 12 days, there were no differences in PE incidence, major bleeding, or death between the LMWH or unfractionated heparin.

2 Year Follow-Up: At two years post-randomization, patients with IVC filter had significantly more DVT compared to no filter (20.8% vs. 11.6%, OR: 1.87, CI: 1.10-1.45), p = 0.02.  There were no differences in symptomatic PE or mortality.  For patients treated initially with UFH or LMWH, there were no differences in outcomes after two years.

Discussion: This trial shows that while IVC filter may prevent PE in the short term, presence of a filter increases risk of DVT in the long term.  The paper also shows that on average, there is no difference between LMWH and UFH for acute treatment of DVT.  The trial still leaves open the possibility though that an IVC filter inserted for the short tem may decrease the incidence of PE.  While there was no difference in mortality between the two groups, a larger cohort may have shown mortality benefit in addition to the short-term decrease in PE.  This question, however, is probably going to be hard to address since this trial is one of the very few randomized trials evaluating IVC filter.  Perhaps, the makes of the IVC filter may be interested in supporting such a trial!

Monday, August 13, 2012

A Plavix a Day Keeps MI Away?

Motivation: Last week, I was trying to coax a patient into taking aspirin every day, and he refused to give way.  He had stomach pain after every dose of aspirin.  To me, it seemed reasonable to refuse aspirin, but then again, I did not want his next stroke on my conscience either.  I wondered if there was a way out or even a better way.  How good is clopidogrel compared to aspirin for prevention of vascular events in high risk populations?

Paper: CAPRIE Steering Committee, "A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)" Lancet (1996); 348: 1329-39.

Methods: Randomised blinded trial of 19,185 adults in USA, Canada, and Europe with symptomatic atherosclerotic peripheral arterial disease, recent MI (within 5 weeks), or recent ischemic stroke (within 6 months).  Patients with bleeding disorders were excluded.  Patients were randomized to clopidogrel 75 mg daily or aspirin 325 mg daily.  Primary outcome was ischemic stroke, MI, or vascular death.  Secondary outcomes included all-cause mortality, intracranial hemorrhage, fatal bleeds, and other clusters of outcomes.  Mean duration of follow-up was 1.91 years.

Results: 
Cohort: Among 19,185 patients, 9,586 were randomized to aspirin while 9,599 were randomized to clopidogrel.  Mean age of cohort was 62.5 years, and the cohort was 72% male and 95% white.  Baseline characteristics of the patients in terms of comorbidities were evenly balanced.  Prior to end of study, 21.3% in clopidogrel group and 21.1% in aspirin group discontinued drug.  Most common cause for stopping was adverse drug effect.

Primary Outcome: For the primary outcome of ischemic stroke, MI, or vascular death, the average event rate per patient year was 5.32% in clopidogrel group and 5.83% in aspirin, yielding a relative risk reduction of 8.7% (95% CI 0.3-16.5%, p = 0.043), in favor of clopidogrel.

Secondary Outcome: For the pre-defined secondary outcome measures of vascular death, death from any cause, or cluster of ischemic/hemorrhagic stroke, MI, and death, there was no difference between aspirin and clopidogrel.

Post-Hoc Analysis: In post-hoc subgroup analysis, patients with peripheral arterial disease benefited the most from clopidogrel over aspirin.  The relative risk reduction for clopidogrel over aspirin for primary outcome was 23.8% (CI: 8.9 to 36.2), p = 0.0028.  For patients with MI or stroke, the effect of clopidogrel over aspirin was non-significant.

Adverse Effects: Frequency of rash was higher in clopidogrel over aspirin whereas GI bleed was more frequent in aspirin users.

Discussion: For secondary prevention of vascular events, clopidogrel is at least as good as aspirin.  What was surprising in the post-hoc analysis was the apparent benefit of clopidogrel over aspirin in patients with PAD but not in post-MI and post-stroke patients.  I think that this finding is a note of caution that atherosclerosis in all vascular territories is not equivalent, and benefit of a drug in a type of vascular disease does not necessarily generalize.  The trial was generally well-done, but the 21% rate of drug discontinuation in both groups remains a concern and may have masked beneficial effects in intention-to-treat analysis.  In summary, if a patient balks against aspirin for secondary prevention, daily clopidogrel is an equivalent option and may even be better if patient has PAD.

Tuesday, August 7, 2012

Keppra for Subdurals

Motivation: As a medicine intern last year, I often scoffed at the algorithmic recommendation by neurosurgery of Keppra for seven days after every small subdural hemorrhage.  Two nights ago, I self-consciously found myself writing the same recommendation while consulting as neurology for a patient after a fall.  What is the data?

Turns out that there is no high quality randomized trial testing anti-epileptics in acute sub-dural hematomas.  The practice is drawn from literature in traumatic brain injury.

Paper: Chang, B.S. and Lowenstein, D.H.  "Practice Parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury." Neurology (2003); 60: 10-16.

Method: A meta-analysis of prospective placebo controlled trials testing anti-epileptic drugs in traumatic brain injury.  Literature search revealed that data existed only for severe TBI - typically with loss of consciousness or amnesia for 12 to 24 hours, depressed skull fracture, or brain contusion on CT scan.  No constraint was placed on the choice of AED.  Authors separated analysis by prevention of early or late seizures.

Results:
Prevention of Early Seizures: Four randomized trials examined early (less than 7 days) prevention of seizure from TBI.  Three studies used phenytoin and one used carbamazepine.   The pooled RR for seizure on AED compared to placebo was 0.37 (CI: 0.18-0.74).  Of the four studies, one did not find any benefit with AED though that study was hindered by low event rate.  There was no significant increase in frequency of adverse effects in group taking AED.

Prevention of Late Seizures: Five high quality trials tested long-term AED for prevention of seizures.  The treatment duration was 6 months to 2 years (most trials were 1-2 years) with median follow-up of 2 years (five trials) with range of 18 months to 2 years.  Trials used phenytoin, carbamazepine, or valproic acid.  The pooled RR for seizure on AED compared to placebo was 1.05 (CI: 0.82-1.35) demonstrating no benefit - none of the individual studies showed benefit.  Some unblinded studies (not included in pooled analysis) showed benefit.  Adverse effects (particularly rash) was significantly higher in the intervention group than placebo group.

Discussion: In severe TBI, anti-epileptic drugs appear beneficial in preventing seizures in the short term (7 days) but ineffective in the long-term.  This landmark meta-analysis, though, has been commonly extended to justify prescribing anti-epileptics for many minor to mild TBI without changes in consciousness or brain contusions.  Although probably beneficial, the practice is still more opinion based rather than evidence based.    Also, the trials used mostly phenytoin as the anti-epileptic of choice while current practice is more heavily biased towards levetiracetam (Keppra).  While I do not plan to rebel against the seven day course of Keppra for subdurals, there is need for data in this common clinical situation.

Monday, July 16, 2012

New Way for Hypertension

Motivation: Last weekend, I was flipping through an old issue of TIME magazine when I noticed an article with large picture of pink kidneys.  Wondering why TIME magazine would be concerned with urine production, I read a little more and learnt about a "revolutionary" new treatment for hypertension discovered in England in 2010.  The article refers to amazing results published in a trial in Lancet in 2010 from renal sympathetic ablation.  Throughout intern year, we had never seriously considered this therapy.  Why? How good is the data?

Paper: Symplicity HTN-2 Investigators. "Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial" Lancet (2010); 376: 1903-09.

Methods: Multicenter randomized unblinded trial of renal denervation with treatment resistant hypertension, defined as SBP > 160 mmHg (SBP > 150 with DM2) despite compliance on 3 or more anti-hypertensives.  Important exclusion criteria were GFR < 45 and history of MI, unstable angina, or stroke.  Study conducted at Europe, Australia, and New Zealand.  Patients randomized to renal denervation had endovascular catheter directed radioablation through renal artery access.  Primary endpoint was change in average office-based SBP from baseline to 6 months.

Results:
Cohort: In total, 52 patients were randomized to renal denervation while 54 were in the control group.  The two groups were overall similar except for differences in gender (35% female in intervention vs. 50% in control group) and difference in baseline GFR (77 ml/min in intervention vs. 86 in control group). Three patients were lost to follow-up in each group.

Efficacy: In per-protocol analysis, at six-months, renal denervation resulted in mean decrease in BP of 33/11 mmHg compared to no changed in the control group.  The baseline was 178/96 in the intervention group and the same in the control group.  The result is statistically significant, p < 0.0001.  Similar changes were noted in BP measurements at home-based and 24 hour ambulatory measurements.  At least 84% of patients in intervention group had >10 mmHg decrease in SBP at 6 months.

Secondary End Points: There were no differences in serum creatinine, eGFR, and cystatin C between baseline and 6 months in both groups.  There were no differences in composite cardiovascular between the two groups.

Safety: No serious procedure-related or device related complications noted in the six month follow-up.

Discussion: In this preliminary phase trial of renal denervation, the procedure appears remarkably efficacious.  The degree of BP measurement is clearly better than any other current medicinal or lifestyle approach.  Yet, before adopting this intervention, the paper has multiple limitations that need to be clarified.  First, the control and intervention groups were different some important baseline parameters such as gender distribution and GFR.  Second, there were no hard endpoints used in the paper such as MI or long-term cardiovascular outcomes.  It is unclear whether renal denervation has any long-term risks that may outweigh short-term benefits in BP reduction.  Finally, this entire study was funded, designed, and analyzed by Ardian, the maker of the denervation catheter.  The data would gain more integrity if the trial was designed and analyzed independently.  Thus, this therapy is promising but needs a larger follow-up trial before widespread use.